WebApr 27, 2024 · SEATTLE, April 27, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced data from its fusogen technology platform, which are being presented at the virtual American Society of Gene & Cell Therapy (ASGCT) Annual … WebMar 17, 2024 · GENE REPAIR-FOCUSED SANA GARNERS $588M IN INITIAL PUBLIC OFFERING. Sana Biotechnology, the developer of platforms designed to repair and control genes within cells, as well as replace any cell in the body, has raised $587.5 million through an initial public offering (IPO) that could climb as high as $675.6 million.. The company …
Gene therapy SanaGen B.V.
WebJun 2, 2024 · Less than a year after announcing big plans to build out gene therapy manufacturing space in Fremont, Sana Biotechnology Inc. says it will instead set up production in Bothell, Washington, a ... WebSana is building differentiated capabilities across the spectrum of cell and gene therapy. Three aspirations drive Sana as we look to discover treatments for patients with poor … empowered clinic
Gene editing to prevent ventricular arrhythmias associated with ...
WebMay 26, 2024 · Lyell could become the 10th cell or gene therapy maker to go public in 2024, which would far outpace any of the past four years, ... Sana raised more than $700 million while privately held, was co-founded by Juno executives Steve Harr and Hans Bishop, and its top investor was Arch Venture Partners, the VC firm that originally backed Juno. ... WebApr 27, 2024 · SEATTLE, April 27, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as … WebJun 1, 2024 · Sana Biotechnology, Inc. is focused on creating and delivering engineered cells as medicines for patients. We share a vision of repairing and controlling genes, replacing missing or damaged... empowered committee on transmission